A new Vanderbilt study shows that the over-the-counter supplement melatonin is promising in helping children with autism spectrum disorders (ASD), and their families, sleep better.
The study, published in the Journal of Autism and Developmental Disorders, contributes to the growing literature on supplemental melatonin for insomnia in ASD, according to lead author Beth Malow, M.D., M.S., professor of Neurology and Pediatrics, Burry Chair in Cognitive Childhood Development and Vanderbilt Kennedy Center investigator.
Malow said the study was designed to allow researchers to identify doses at which children responded to melatonin and also how long it took to observe a response.
Sleep difficulties, particularly insomnia, occur in 50 percent to 80 percent of children with ASD and are often accompanied by child and family distress.
“We are excited about the potential melatonin has for treating insomnia, which can be overwhelming to children with autism as well as their families,” Malow said.
“The next step is to perform large-scale, controlled trials to prove that melatonin is effective in this population.”
Malow and colleagues recruited children ages 3-9 years with a clinical diagnosis of an ASD whose parents reported sleep onset delay of 30 minutes or longer on three or more nights per week.
Supplemental melatonin, given 30 minutes before bedtime, improved sleep latency in most children at 1 mg or 3 mg dosages.
Sleep latency, or the amount of time it takes a child to fall asleep, was measured by using an actigraph, which is a wrist-watch-like sensor worn by participants to monitor human rest/activity cycles.
Melatonin was effective in the first week of treatment, maintained effectiveness over several months, was well-tolerated and safe, and showed improvement in sleep, behavior and parenting stress, Malow said.
No comments:
Post a Comment